Nicholas Walrod
Managing Director and Founder @ 3×5 Partners
Portland, United States
Nicholas Walrod is a Series A investor at 3×5 Partners in Portland focused on Life Science and Biotechnology. Mr. Nicholas Walrod serves as Principal of 3x5 Special Opportunity Fund, L.P. Mr. Walrod serves at RiverVest Venture Partners, LLC. He has been a Director of Securus Medical Group, Inc. since October 29, 2013.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Nicholas Walrod invests in
Stages Nicholas Walrod invests in
Countries Nicholas Walrod invests in
Investment Focus
Industry
- Life Science 3 (23%)
- Biotechnology 3 (23%)
- Environmental Engineering 2 (15%)
- Energy 1 (8%)
- Medical 1 (8%)
Stage
- Series A 4 (31%)
- Series B 3 (23%)
- Series C 2 (15%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Bonum Therapeutics
|
Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management. | $93M / Series A / Nov 15, 2022 | |
|
Bonum Therapeutics
|
Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management. | $93M / Series A / Nov 15, 2022 | |
Fervo Energy
|
Fervo Energy is a next-generation geothermal developer generating clean power in new places. Fervo Energy commercializes proprietary technology to own, develop, and operate geothermal assets as the dispatchable foundation to a 100% clean energy future. | $138M / Series C / Aug 22, 2022 | |
|
Fervo Energy
|
Fervo Energy is a next-generation geothermal developer generating clean power in new places. Fervo Energy commercializes proprietary technology to own, develop, and operate geothermal assets as the dispatchable foundation to a 100% clean energy future. | $138M / Series C / Aug 22, 2022 | |
Good Therapeutics
|
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer,more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology. | $8M / Series B / Dec 30, 2021 | |
Claros Technologies
|
Claros Technologies is an environmental technology company that develops solutions for the detection, analysis, and destruction of per- and polyfluoroalkyl substances (PFAS). The company provides PFAS testing and analytical laboratory services, proprietary PFAS destruction technology, and regulatory compliance solutions for industrial, municipal,and government organizations. Its technologies are designed to help identify, manage, and permanently eliminate PFAS contamination from water, wastewater, and other materials through science-based environmental remediation solutions. | $5.5M / Series A / Aug 04, 2021 | |
|
Claros Technologies
|
Claros Technologies is an environmental technology company that develops solutions for the detection, analysis, and destruction of per- and polyfluoroalkyl substances (PFAS). The company provides PFAS testing and analytical laboratory services, proprietary PFAS destruction technology, and regulatory compliance solutions for industrial, municipal,and government organizations. Its technologies are designed to help identify, manage, and permanently eliminate PFAS contamination from water, wastewater, and other materials through science-based environmental remediation solutions. | $5.5M / Series A / Aug 04, 2021 | |
|
Fervo Energy
|
Fervo Energy is a next-generation geothermal developer generating clean power in new places. Fervo Energy commercializes proprietary technology to own, develop, and operate geothermal assets as the dispatchable foundation to a 100% clean energy future. | $28M / Series B / Apr 30, 2021 | |
|
Fervo Energy
|
Fervo Energy is a next-generation geothermal developer generating clean power in new places. Fervo Energy commercializes proprietary technology to own, develop, and operate geothermal assets as the dispatchable foundation to a 100% clean energy future. | $11M / Series A / Jul 03, 2019 | |
|
Good Therapeutics
|
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer,more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology. | $11.2M / Series A / Jan 31, 2019 | |
| See all 13 investments → | |||
Co-Investors
About 3×5 Partners
3×5 Partners is a venture capital firm that focuses on innovations in the life science and resource-driven sectors. It identifies companies that reduce and evolve the consumption of the planet’s limited resources, including energy, food, waste, water, and other natural resources. It seeks opportunities in the life-science sector to improve patientoutcomes by developing innovations in biopharma and medical devices. It believes that these solution leaders will become some of the most valuable companies in the future.The firm was founded in 2011 and is headquartered in Portland, Oregon.
3×5 Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anthony Arnerich
Managing Director and Founder
|
|||
|
Nicholas Walrod
Managing Director and Founder
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Nicholas Walrod invest in?
Nicholas Walrod invests primarily in Life Science, Biotechnology and Environmental Engineering startups, most often at Series A and Series B stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Nicholas Walrod last invest?
The most recent investment recorded for Nicholas Walrod closed in Nov 2022. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
